Jan 18, 2024 7:00 am EST New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
Jan 14, 2024 4:30 am EST Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
Jan 9, 2024 7:00 am EST Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
Jan 7, 2024 8:00 pm EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
Dec 20, 2023 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 1, 2023 7:00 am EST Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
Nov 14, 2023 7:00 am EST Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
Nov 13, 2023 7:00 am EST Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
Nov 8, 2023 4:30 pm EST Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
